Release Date: February 25, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: What's contemplated in the guide in terms of the Yuwell agreement throughout 2025, and how will it impact gross margins? A: Michael Bourque, CFO, explained that the Yuwell agreement is not expected to significantly impact 2025 results as the deal just closed. The gross margin impact relates to the introduction of Yuwell and Simeox products, along with some raw material costs, amounting to about 100 basis points. The revenue from Yuwell is minimal in the 2025 guidance.
Q: How should we think about the breakdown of revenue guidance between different segments like DTC and B2B? A: Michael Bourque stated that while they don't provide specific guidance by revenue channel, the B2B business is expected to continue being a major growth driver, albeit not at the 30% growth rate seen in 2024. The DTC channel will continue to see reduced revenue due to a smaller sales force, with improvements expected in the latter half of 2025.
Q: What is the expected revenue cadence throughout 2025? A: Michael Bourque noted that Q2 and Q3 are traditionally the strongest quarters for revenue, particularly in the DTC segment, while Q1 and Q4 face seasonal challenges. This pattern is expected to continue in 2025.
Q: How will Yuwell's product portfolio be introduced in the US, and will it require incremental investment? A: Kevin Smith, CEO, explained that Yuwell's products, starting with the stationary oxygen concentrator, will be branded as Inogen and sold across all channels without needing additional sales force investment. This will enhance the rental and B2B segments and offer cash sales opportunities in the DTC channel.
Q: Can you provide more details on the Simeox launch strategy and engagement with private insurers? A: Kevin Smith highlighted ongoing clinical trials in Europe and plans for US reimbursement. The strategy involves engaging key opinion leaders and private insurers to maximize reimbursement, with a focus on ensuring comprehensive data and support for CMS submissions.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.